Skip to main content
Top
Published in: Reactions Weekly 1/2023

01-12-2023 | Hepatitis | Case report

Pembrolizumab

Various toxicities: 18 case reports

Published in: Reactions Weekly | Issue 1/2023

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literature
go back to reference Ksienski D, et al. Safety and efficacy of pembrolizumab for advanced nonsmall cell lung cancer: before and during the COVID-19 pandemic. Journal of Cancer Research and Clinical Oncology 149: 2951-2961, No. 7, Jul 2023. Available from: URL: http://doi.org/10.1007/s00432-022-04181-0 Ksienski D, et al. Safety and efficacy of pembrolizumab for advanced nonsmall cell lung cancer: before and during the COVID-19 pandemic. Journal of Cancer Research and Clinical Oncology 149: 2951-2961, No. 7, Jul 2023. Available from: URL: http://​doi.​org/​10.​1007/​s00432-022-04181-0
Metadata
Title
Pembrolizumab
Various toxicities: 18 case reports
Publication date
01-12-2023
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-51669-x

Other articles of this Issue 1/2023

Reactions Weekly 1/2023 Go to the issue

Case report

Tisagenlecleucel

Case report

Flumbatinib

Case report

Adenosine

Case report

Immunotherapies